Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

被引：6

作者：

Roussel, Murielle ^{[1
,2
]}

Hebraud, Benjamin ^{[1
,2
]}

Hulin, Cyrille ^{[3
]}

Leleu, Xavier ^{[4
]}

Facon, Thierry ^{[5
]}

Boyle, Eileen ^{[6
]}

Touzeau, Cyrille ^{[7
]}

Pegourie, Brigitte ^{[8
]}

Perrot, Aurore ^{[9
,10
]}

Stoppa, Anne-Marie ^{[11
]}

Marolleau, Jean-Pierre ^{[12
]}

Moreau, Philippe ^{[13
]}

Avet-Loiseau, Herve ^{[14
]}

Devlamynck, Laure ^{[15
]}

Lauwers-Cances, Valerie ^{[15
]}

Attal, Michel ^{[1
,2
]}

机构：

[1] Inst Univ Canc, Toulouse, France

[2] Univ Hosp, Toulouse, France

[3] Hop Haut Leveque, Dept Hematol, Pessac, France

[4] CHU Poitiers, Serv Hematol & Therapie Cellulaire, Poitiers, France

[5] Hop Claude Huriez, Hosp Huriez, Serv Malad Sang, Lille, France

[6] CHU Lille, Dept Hematol, Lille, France

[7] CHU Nantes, Nantes, France

[8] Ctr Hosp Univ CHU Grenoble, Dept Hematol, Grenoble, France

[9] Hop Brabois, Vandoeuvre Les Nancy, France

[10] Univ Hosp, Dept Hematol, Vandoeuvre Les Nancy, France

[11] Inst Paoli Calmettes, Marseille, France

[12] Amiens Univ Hosp, Dept Hematol, Amiens, France

[13] Univ Hosp Hotel Dieu, Clin Hematol, Nantes, France

[14] IUC T Oncopole, Unite Genom Myelome, Toulouse, France

[15] CHU Toulouse, Serv Epidemiol, USMR, Toulouse, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123184

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3159

引用

页数：4

共 36 条

[21] Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Chretien, Marie-Lorraine
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S25 - S25
[22] A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment
Terpos, Evangelos
Kastritis, Efstathios
Symeonidis, Argiris
Pouli, Anastasia
Delimpasi, Sosana
Katodritou, Eirini
Hatzimichael, Eleftheria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Manousou, Kyriaki
Gavriatopoulou, Maria
Dimopoulos, Meletios A.
BLOOD, 2023, 142
[23] Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Caillot, Denis
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Chretien, Marie-Lorraine
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Corre, Jill
Jobert, Alexandra
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
BLOOD, 2023, 142
[25] Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen
Rifkin, Robert M.
Boccia, Ralph V.
Kambhampati, Suman
Richter, Joshua R.
Usmani, Saad Z.
Aiello, Jack
Sickler, Brittany
Schoeneich, Magdalena
Wang, Bingxia
Zelt, Susan
Whidden, Presley
Dollar, Lawrence E.
Niculescu, Liviu
Noga, Stephen J.
BLOOD, 2017, 130
[26] An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne A.
Reeves, Brandi
Wildes, Tanya M.
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf Z.
Shune, Leyla O.
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 10154 - 10156
[27] Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group
Terpos, Evangelos
Katodritou, Eirini
Symeonidis, Argiris
Zagouri, Flora
Gerofotis, Antonis
Christopoulou, Georgia
Gavriatopoulou, Maria
Christoulas, Dimitrios
Kourakli, Alexandra
Konstantinidou, Pavlina
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2016, 128 (22)
[28] Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study
Kazandjian, Dickran
Korde, Neha S.
Roschewski, Mark
Mailankody, Sham
Morrison, Candis
Manasanch, Elisabet E.
Kwok, Mary L.
Tageja, Nishant
Bhutani, Manisha
Zingone, Adriana
Costello, Rene
Zhang, Yong
Mulquin, Marcia
Lamping, Liz
Carpenter, Ashley
Roberson, Brenda
Maric, Irina
Calvo, Katherine R.
Braylan, Raul C.
Yuan, Constance M.
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Lindenberg, Liza
Kurdziel, Karen A.
Choyke, Peter
Steinberg, Seth M.
Figg, William
Wilson, Wyndham H.
Landgren, Ola
BLOOD, 2016, 128 (22)
[29] Twice-Weekly Oral MLN9708 (Ixazomib Citrate), A Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data
Richardson, Paul G.
Hofmeister, Craig C.
Rosenbaum, Cara A.
Htut, Myo
Vesole, David H.
Berdeja, Jesus
Liedtke, Michaela
Chari, Ajai
Smith, Stephen D.
Lebovic, Daniel
Berg, Deborah
Liao, Eileen
Gupta, Neeraj
Di Bacco, Alessandra
Estevam, Jose
Hui, Ai-Min
Baz, Rachid
BLOOD, 2013, 122 (21)
[30] In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study
Girnius, Saulius K.
Richter, Joshua
Lyons, Roger
Bogard, Kimberly
Manda, Sudhir
Birhiray, Ruemu E.
Yimer, Habte A.
Tran, Kim
Kambhampati, Suman
Arora, Jyoti
Noga, Stephen J.
Rifkin, Robert M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S501 - S501

← 1 2 3 4 →